ClinicalTrials.gg
RecruitingNCT07601087Updated Aug 24, 2026

A Clinical Study of HRS-7156 in Healthy Participants

A Phase 1 interventional study of HRS-7156 and HRS-7156 placebo in Heart Failure, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-7156 in healthy participants.

02

Conditions studied

  • Heart Failure

Browse trials for

03

In context

Heart Failure

6,331 studies on the registry are indexed under Heart Failure; 1,396 are open to participants now.

This study's planned enrollment of 66 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy men and women aged 18 to 55 years old at signing;
  2. Male body weight ≥50 kg, female ≥45 kg; 18.5 to 30 kg/m² at screening and baseline;
  3. Have no abnormalities at screening and baseline;
  4. Fertile females and males with fertile female partners: effective 2 weeks before consent, and sustained until 1 week after the last dose (abstinence or highly effective contraception); no sperm/egg donation.

Exclusion criteria

Exclusion Criteria:

  1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results;
  2. Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial;
  3. Blood donation/severe blood loss (≥400 mL) within 8 weeks, blood transfusion within 4 weeks before screening; planned blood donation during the trial;
  4. History of drug abuse/dependence; positive urine drug test at screening.Participation in other clinical trials within 3 months before screening or planned;
  5. participation during the trial; within 5 half-lives of a prior drug (whichever is longer);
  6. Smoking history (≥5 cigarettes/day) within 4 weeks before screening; inability to abstain from tobacco during the trial; positive smoke screening at screening/baseline;
  7. Positive for , antibody, Treponema pallidum antibody or antibody at screening;
  8. Special dietary requirements and inability to comply with the unified diet;
  9. Difficulty in swallowing/venous blood collection; intolerance to intensive blood sampling;
  10. Other circumstances deemed unsuitable for trial participation by Researcher.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    HRS-7156

    Drug: HRS-7156

  • Placebo comparator
    HRS-7156 placebo

    Drug: HRS-7156 placebo

Interventions

  • DrugHRS-7156

    HRS-7156, specified dose on specified day.

  • DrugHRS-7156 placebo

    HRS-7156 placebo, specified dose on specified day.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse event (AE) and serious adverse event (SAE)

    Safety: Incidence of adverse event (AE) and serious adverse event (SAE).

    Time frame: Up to 14 days.

Secondary outcomes

  1. Area under the concentration time curve (AUC)

    Pharmacokinetics (PK) parameter of HRS-7156.

    Time frame: Day 1 - Day 9.

  2. Maximum Plasma Concentration (Cmax)

    Pharmacokinetics (PK) parameter of HRS-7156.

    Time frame: Day 1 - Day 9.

  3. Time to maximum plasma concentration (Tmax)

    Pharmacokinetics (PK) parameter of HRS-7156.

    Time frame: Day 1 - Day 9.

  4. Renal clearance (CLR)

    Pharmacokinetics (PK) parameter of HRS-7156.

    Time frame: Day 1 - Day 2.

  5. Renin concentration of HRS-7156

    Pharmacodynamics (PD) endpoint of HRS-7156.

    Time frame: Day 1 - Day 9.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07601087
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Jun 12, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 24, 2026

Study contacts

Kaiyun Zhang
Contact
kaiyun.zhang.kz38@hengrui.com
+86-0518-82342973
Sheng Qi
Contact
sheng.qi@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion